echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > International Vision | Liver Cancer: Double-immune treatment data is updated again, liver cancer patients usher in "warm spring"

    International Vision | Liver Cancer: Double-immune treatment data is updated again, liver cancer patients usher in "warm spring"

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Dr.
    Daniel Lin from the Sidney Kimmel Cancer Center pointed out that the results of the Phase III IMbrave150 study and the Phase I/II CheckMate-040 study mutually confirmed the efficacy and role of immune combination therapy in hepatocellular carcinoma (HCC).

    In this article, Dr.
    Daniel Lin focuses on the important immunotherapies for HCC patients, as well as other immunotherapies that show new hope [1].

    In May 2020, the U.
    S.
    Food and Drug Administration (FDA) approved atelizumab + bevacizumab for the first-line treatment of patients with unresectable or metastatic HCC.

    IMbrave150 updated data showed that the median overall survival (OS) of atilizumab + bevacizumab versus sorafenib was 19.
    2 months and 13.
    4 months (HR=0.
    66), respectively.
    The bit progression-free survival (PFS) was 6.
    9 months and 4.
    3 months (HR=0.
    65) [2].

    Looking forward to the latest data of IMbrave150 research at the upcoming AACR conference.

    Based on the early results of the Phase I/II CheckMate-040 study, in March 2020, the FDA approved nivolumab + ipilimumab for HCC patients who have previously received sorafenib treatment.

    The latest data show that at a median follow-up of 44 months, the objective response rate (ORR) of nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) reached 30%, and the median OS reached 22.
    2 months [3].

    Dr.
    Daniel Lin pointed out that there are currently a variety of options for the treatment of patients with advanced HCC, but it is still unclear whether patients who have previously received PD-1 inhibitors respond to PD-1 inhibitors + CTL-4 inhibitors, and more are needed.
    research data. Implications from the IMbrave150 study and the CheckMate-040 study.
    These two studies have established the role of immune checkpoint inhibitors in HCC patients in a true sense.

    Compared with nivolumab and pembrolizumab for first-line treatment, these two studies and their results are impressive.

    For the IMbrave150 study, compared with sorafenib, atelizumab + bevacizumab for first-line treatment of liver cancer patients had better ORR and OS.

    The CheckMate-040 study showed that nivolumab + ipilimumab showed better anti-tumor activity when used in the second-line and above treatment of liver cancer, especially in Child-Pugh A patients.

    The median OS of the joint program reached nearly 2 years, which surpassed previous historical data.

    The IMbrave150 and CheckMate-040 studies have truly consolidated the stable position of the immune combination program in HCC patients.

    The new revelation of IMbrave150 updated data IMbrave150 suggests that compared with sorafenib, atilizumab+bevacizumab has an earlier response time.

    What is more noteworthy is that the possibility of remission (partial remission or complete remission) is higher with combination therapy, about 30%.

    In previous studies on TKI, the best remission is often stable disease (SD) with a smaller degree of tumor shrinkage.

    Nivolumab + Ipilimumab applicable population The main population in the CheckMate-040 study is sorafenib refractory population.

    Whether nivolumab + ipilimumab is the choice after atelizumab + bevacizumab treatment fails is one of the key issues that still need to be resolved.

    A small sample of studies has shown that in patients who have previously received at least one PD-1 inhibitor, continued addition of CTLA-4 can potentially overcome drug resistance, and patients can continue to respond to treatment.

    Similar results have been observed in other tumors such as melanoma and renal cell carcinoma.

    The immunotherapy regimen of Study 22 At present, the duvalimab+tremelimumab regimen explored in Study 22 cannot change current clinical practice.

    The phase III HIMALAYA study explored the efficacy of duvalizumab + tremelimumab in the first-line treatment of liver cancer, and we look forward to the announcement of the results of the study.

    The prospect of immune combination therapy Atelizumab+bevacizumab has very good results in the first-line treatment of HCC and is well tolerated.

    Currently, other first-line treatments are being explored: LEAP research, COSMIC research, for example.

    Ultimately, researchers will directly or indirectly compare the efficacy of these immune combination treatments, including response, duration of remission, and tolerance.

    This will provide new ideas for how to choose the best first-line immune combination therapy for liver cancer patients.

    References: 1.
    Updated Data Confirm Clinical Benefit of Novel Immunotherapy Combos in HCC.
    April 7, 2021.
    onclive.
    2.
    Finn RS, Qin S, Ikeda M, et al.
    IMbrave150: updated overall survival (OS) data from a global , randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC) 3.
    El-Khoueiry AB, Yau T, Kang YK, et al.
    Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): long-term results from CheckMate 040.
    J Clin Oncol.
    2021;39(suppl 3):269.
    doi :10.
    1200/JCO.
    2021.
    39.
    3_suppl.
    269
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.